CFO of Coeptis Therapeutics (COEP) boosts stake via options and stock grant

Rhea-AI Filing Summary

Coeptis Therapeutics Holdings, Inc. Chief Financial Officer Brian Cogley increased his direct ownership of common stock through an option exercise and an equity grant. On February 11, 2026, he exercised stock options to acquire 10,000 shares of common stock at an exercise price of $10.56 per share, converting derivative securities into shares.

On the same date, he also received a grant of 12,500 shares of restricted stock in connection with an option exchange program, where previously granted underwater options were surrendered in exchange for restricted stock. Following these transactions, he directly beneficially owned 22,500 shares of common stock.

Insights

Equity compensation and insider-transactions analyst

CFO increased direct share ownership via option exercise and restricted stock grant, with no open-market buying or selling.

The filing shows Coeptis Therapeutics CFO Brian Cogley exercised stock options to acquire 10,000 common shares at an exercise price of $10.56 per share. This is labeled as an exercise or conversion of derivative securities, not an open-market purchase. The transaction shifts value from options into actual shares.

He also received 12,500 restricted shares in an option exchange program, surrendering underwater options for equity that vests as stock. After these actions, he directly owned 22,500 common shares. Because these are internal compensation and restructuring moves, without disclosed sales or cash proceeds, the overall impact on shareholders is routine and administrative.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Cogley Brian

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Common stock	10,000	$10.56	$106K
Grant/Award	Common Stock	12,500	$0.00	--

Holdings After Transaction: Common stock — 22,500 shares (Direct); Common Stock — 22,500 shares (Direct)

Footnotes (1)

1. Represents the exercise price of shares purchased upon exercise of stock options. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cogley Brian

(Last) (First) (Middle)

105 BRADFORD ROAD, SUITE 420

(Street)

WEXFORD PA 15090

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coeptis Therapeutics Holdings, Inc. [ COEP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	02/11/2026		M		10,000	A	$10.56(1)	22,500	D
Common Stock	02/11/2026		A		12,500	A	$0(2)	22,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the exercise price of shares purchased upon exercise of stock options.

2. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

	/s/ Brian Cogley	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did COEP CFO Brian Cogley report on February 11, 2026?

He reported acquiring common stock through two transactions on February 11, 2026. He exercised options for 10,000 shares at $10.56 per share and received a grant of 12,500 restricted shares as part of an option exchange program.

How many Coeptis Therapeutics (COEP) shares does the CFO own after this Form 4?

After the reported transactions, the Chief Financial Officer beneficially owned 22,500 shares of Coeptis Therapeutics common stock directly. This reflects both the 10,000 shares from option exercise and the 12,500 restricted shares granted in the option exchange program.

Did the COEP CFO buy or sell shares on the open market in this Form 4?

The transactions did not involve open-market buying or selling. One transaction was an option exercise converting derivative securities into 10,000 common shares, and the other was a grant of 12,500 restricted shares under an option exchange program for surrendered underwater options.

What was the exercise price for the COEP stock options exercised by the CFO?

The options were exercised at an exercise price of $10.56 per share. Exercising these options resulted in the acquisition of 10,000 shares of Coeptis Therapeutics common stock, as disclosed in the Form 4 insider transaction report.

What is the nature of the 12,500 restricted COEP shares granted to the CFO?

The 12,500 restricted shares were issued as part of an option exchange program. In this program, the CFO surrendered previously granted underwater options and received restricted stock instead, aligning compensation with actual share ownership rather than out-of-the-money options.

Is the COEP CFO’s ownership in these shares direct or indirect?

The Form 4 indicates that all 22,500 shares beneficially owned following the transactions are held with direct ownership. There is no footnote indicating indirect ownership through entities such as trusts, partnerships, or family investment vehicles.